Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study
Joint Authors
Source
Journal of the Egyptian National Cancer Institute
Issue
Vol. 26, Issue 4 (31 Dec. 2014), pp.195-202, 8 p.
Publisher
Cairo University National Cancer Institute
Publication Date
2014-12-31
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Topics
Abstract EN
The aim of this study is to investigate efficacy and toxicity of 1 year of capecitabine metronomic therapy preceded by standard adjuvant chemotherapy in triple-negative breast cancer (TNBC) patients.
Methods : Between June 2010 and February 2012, 19 women with pathologically proven operable TNBC, who had received standard adjuvant chemotherapy before were enrolled.
Patients received 1 year of oral capecitabine metronomic therapy (650 mg / m2, twice every day), after standard adjuvant chemotherapy and radiotherapy if indicated.
The primary endpoints of this study were disease-free survival rates (DFS) and safety profile.
Secondary end point was overall survival (OS).
Results : The maximal follow-up was 46.6 months with a median of 30.1 months ± 11.525 (95 % CI ; 28.5–33.5 months).
The median DFS was 41.7 months ± 2.7 (95 % CI ; 36.5–46.9).
No one developed locoregional recurrence.
The actuarial rate of DFS was 88.8 % and 82.05 % at 2 and 3 years, respectively.
At the time of the analyses, no patients had died and the median OS was not reached.
Treatment-related adverse events were manageable with only 1 patient (5.3 %) suffering from Grade 3 / 4 hand-foot syndrome and another 1 patient (5.3 %) suffering from Grade 3 diarrhea.
No Grade 3 / 4 hematologic toxicity was recorded.
All patients received full doses of capecitabine throughout the study and dose reduction was not required in any of our patients.
Conclusion : One year of capecitabine metronomic therapy preceded by standard adjuvant chemotherapy, is active and well-tolerated in TNBC patients previously treated with standard adjuvant chemotherapy.
American Psychological Association (APA)
Shawqi, Hanan& Jalal, Samar. 2014. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study. Journal of the Egyptian National Cancer Institute،Vol. 26, no. 4, pp.195-202.
https://search.emarefa.net/detail/BIM-428617
Modern Language Association (MLA)
Shawqi, Hanan& Jalal, Samar. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study. Journal of the Egyptian National Cancer Institute Vol. 26, no. 4 ( 2014), pp.195-202.
https://search.emarefa.net/detail/BIM-428617
American Medical Association (AMA)
Shawqi, Hanan& Jalal, Samar. Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy : a singlearm phase II study. Journal of the Egyptian National Cancer Institute. 2014. Vol. 26, no. 4, pp.195-202.
https://search.emarefa.net/detail/BIM-428617
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 200-202
Record ID
BIM-428617